GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » PB Ratio

Outlook Therapeutics (Outlook Therapeutics) PB Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-28), Outlook Therapeutics's share price is $8.43. Outlook Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-1.87. Hence, Outlook Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Outlook Therapeutics's PB Ratio or its related term are showing as below:

During the past 10 years, Outlook Therapeutics's highest PB Ratio was 76.59. The lowest was 2.35. And the median was 14.98.

OTLK's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.38
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Outlook Therapeutics's average Book Value Per Share Growth Rate was -252.40% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Outlook Therapeutics was 48.40% per year. The lowest was 21.20% per year. And the median was 32.30% per year.

Back to Basics: PB Ratio


Outlook Therapeutics PB Ratio Historical Data

The historical data trend for Outlook Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics PB Ratio Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 32.43 83.14 31.73 -

Outlook Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.59 26.68 - - -

Competitive Comparison of Outlook Therapeutics's PB Ratio

For the Biotechnology subindustry, Outlook Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's PB Ratio falls into.



Outlook Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Outlook Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.43/-1.871
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Outlook Therapeutics  (NAS:OTLK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Outlook Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (Outlook Therapeutics) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Executives
Terry Dagnon officer: Chief Operating Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson officer: Chief Commercial Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin director ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian director 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger director 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii director, officer: CEO and President 1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian director, 10 percent owner 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon officer: CFO and Secretary C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc 10 percent owner 1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang director C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth director C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments director C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007

Outlook Therapeutics (Outlook Therapeutics) Headlines

From GuruFocus